1. NIH Consensus Development Panel: Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6): 785-795, 2001.
2. Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 85(1): 231-236, 2000.
3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282(7): 637-645, 1999.
4. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD: Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 17(1): 1-10, 2002.